ClearBridge Cites Thermo Fisher Demand and Guidance for 2027
The growth strategy said resilient biopharma demand and healthy third-quarter guidance supported its outlook for improving business into 2027.
Key takeaways
- ClearBridge named Thermo Fisher a positive contributor in its third-quarter 2026 letter.
- The strategy cited resilient biopharma demand and healthy third-quarter guidance.
ClearBridge Investments said Thermo Fisher Scientific was a positive contributor in the third quarter of 2026, citing resilient demand and healthy guidance.
In its investor letter, the growth strategy said the company benefited from its second-quarter earnings beat. It pointed to demand for biopharma consumables and pharmaceutical product development.
ClearBridge said the breadth of recovery in those markets was important after a difficult period for life sciences spending. It said the trends supported the prospect of an accelerating business into 2027.
This article was produced with the help of AI technology. Source: Yahoo Finance
